Please assess the completion status of the following clinical trial:

Trial Title: VISmodegib for ORbital and Periocular Basal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients over 18 years of age with locally advanced or recurrent orbital or periorbital basal cell carcinoma (BCCA), or a medial canthal BCCA that threatens the lacrimal drainage system.~* Clinical assessment score obtained at baseline.~* Medical Oncology screening performed at baseline.~* Adequate BCCA size and location.~* Adequate hematopoietic capacity, hepatic and renal function.~* Male patients must agree to use condoms during treatment and for 3 months after last dose.~* Male patients must agree to not donate sperm during treatment and for 3 months after last dose.~* Participant must agree not to donate blood during the study and for 7 months after last dose.~* Informed consent signed.~* If the patient consents to enroll, then blood will be drawn and stored for biomarker analysis.~Exclusion Criteria:~* Inability or unwillingness to swallow capsules.~* Inability or unwillingness to comply with study procedures.~* Pregnant, lactating, or breast feeding women.~* Women of childbearing potential.~* Uncontrolled medical illness.~* Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.~* Age under 18 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vismodegib (Type: EXPERIMENTAL): 150mg taken orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).